8/26/2013

GlaxoSmithKline said adverse events increased at a new higher dosage in a trial of vercirnon, an experimental treatment licensed from ChemoCentryx. The findings prompted GSK to suspend new patient recruitment and dosing pending further analysis in the Crohn's disease study. "The results from the SHIELD-1 study are clearly disappointing but we are committed to further explore the data to determine the way forward to help patients with this chronic debilitating gastrointestinal disease," a GSK official said.

Full Story:
Reuters

Related Summaries